Vaccinex Inc (VCNX)
NASDAQ:VCNX
US Market
Holding VCNX?
Track your performance easily

Vaccinex (VCNX) Stock Price & Analysis

286 Followers

VCNX Stock Chart & Stats


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

VCNX FAQ

What was Vaccinex Inc’s price range in the past 12 months?
Vaccinex Inc lowest stock price was $4.43 and its highest was $68.55 in the past 12 months.
    What is Vaccinex Inc’s market cap?
    Currently, no data Available
    When is Vaccinex Inc’s upcoming earnings report date?
    Vaccinex Inc’s upcoming earnings report date is Aug 12, 2024 which is 90 days ago.
      How were Vaccinex Inc’s earnings last quarter?
      Currently, no data Available
      Is Vaccinex Inc overvalued?
      According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Vaccinex Inc pay dividends?
        Vaccinex Inc does not currently pay dividends.
        What is Vaccinex Inc’s EPS estimate?
        Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Vaccinex Inc have?
        Vaccinex Inc has 1,584,300 shares outstanding.
          What happened to Vaccinex Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Vaccinex Inc?
          Currently, no hedge funds are holding shares in VCNX
          ---

          Company Description

          Vaccinex Inc

          Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Te firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline include SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Atara Biotherapeutics
          Exelixis
          MacroGenics
          Novartis
          Popular Stocks
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis